Tenofovir alafenamide (Duemtrino)
Tenofovir alafenamide
Austell Pharmaceuticals (Pty) Ltd
Registration
- Applicant
- Austell Pharmaceuticals (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Duemtrino EACH TABLET CONTAINS EMTRICITABINE 200,0 mg TENOFOVIR ALAFENAMIDE FUMARATE EQUIVALENT TO TENOFOVIR ALAFENAMIDE 25,0 mg | Not listed | 58013458/20.2.8/0134 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Bictegravir
Consolidated Schedules 06 July 2026, line 5495
S4: Dolutegravir
Consolidated Schedules 06 July 2026, line 6100
S4: Emtricitabine
Consolidated Schedules 06 July 2026, line 6178
S4: Rilpivirine
Consolidated Schedules 06 July 2026, line 7808
S4: Tenofovir
Consolidated Schedules 06 July 2026, line 8130
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
Drag to rotate. Structure from PubChem CID 9574768.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.